Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF

Details Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF

1990-01-31

1993-11-23

Nucker, Christine M.

Drug, bio-affecting and body treating compositions

Lymphokine

424 854, A61K 3766, A61K 4505

Patent

active

052642089

ABSTRACT:
The present invention discloses the use of a anti-cachexia agent with an antiviral agent, preferably used as a therapeutic agent in the treatment of viral infections. The anti-cachexia agent acts to potentiate the antiviral activity of the antiviral agent as much as several hundred fold. The anti-cachexia agent also acts to decrease, or halt the anti-proliferative or host destroying activities of the antiviral agent. The most preferred anti-cachexia agent of the present invention is hydrazine sulfate. The most preferred antiviral agent of the present invention is interferon, tumor necrosis factor or any combination thereof.

REFERENCES:
patent: 4650674 (1987-03-01), Aggarwal et al.
Hughes, et al., 1989, "Modulation of Tumor Necrosis factor activities . . . ", Int. J. Immunopharmac. 11(5):501-507.
Moritz, et al., 1989, "Phase I study of recombinant human tumor . . . " Cancer Immunol. Immumother. 29:144-150.
Lenk, et al., 1989, "Phase II clinical trial of high-dose . . . " Cancer Chemotherapy and Pharmacology 24:391-392.
Chlebowski, et al. "Hydrazine sulfate in cancer patients . . . " Cancer 59:406-410, 1987.
Sulis, et al., 1989, "Intralymphatic infusion of interferon . . . " Cancer Chemo. and Pharm. 24:393-394.
Baron, et al., 1987 (eds) In: "The Interferon System . . . " A Current Review pp. 2-17.
Aggarwal et al. (1985) Methods in Enzymology, 116:448-457.
Klostergaard et al. (1985) Biological Abstracts, 80(5): Abstract 40216, p. AB-403.
Klostergaard et al. (1987) Chemical Abstracts, 106(25): Abstract 212340T, p. 521.
Klostergaard et al. (1987) Chemical Abstracts, 106(13): Abstract 100662T, p. 517.
Klostergaard, J. (1987) Lymphokine Research, 6:19-28.
Klostergaard et al. (1987) Cancer Res., 47:2014-2019.
Klostergaard et al. (1985) Journal of Biological Response Modifiers, 4:195-209.
Klostergaard et al. (1987) Journal of Biological Response Modifiers, 6:313-330.
Lane et al. (1990) Annals of Internal Medicine, 112(11):805-811.
Saah et al. (1987) J. Clin. Microbiol., 25(9):1605.
Molecular Biology of the Cell, (2nd ed. 1989), Alberts et al., eds.: p. 251, p. 1204.
Mestan et al. (1986), Nature, 323: 816-819.
G. Semenzato (1990), Brit. J. Cancer 61 (3):354-361.
Stewart, William E., II, (ed) (1979), In: The Interferon System pp. 200-222.
Hughes, et al., (Feb. 9, 1989), FASEB Journal, 3(3):A636.
Babich, et al., (1989), Carcinogenesis, 10(2):265-8.
Silverstein, et al., (1989), Immunopharmacology, 17:37-43.
Gold, (1986), Proc. Annu. Meet. Am. Assoc. Cancer Res., 27:279.
Kim, et al., (1989), Proc. Annu. Meet. Am. Assoc. Cancer Res., 30:A1618.
Gold, et al., (1987), Nutr. Cancer, 9(2-3):59-66.
Dialog search.
Sonnenfeld, et al., (1983), Cancer Res., 43(10):4720-2.
Lahdevirta, et al., (1988), Am J. Med., 85(3):289-91.
Gold, (1989), Proc. Annu. Meet. Am. Assoc. Cancer Res., 30:A2164.
Gold, (1989), Proc. Annu. Meet. Am. Assoc. Cancer Res., 29:A1296.
Stovroff, et al., (1989), J. Surg. Res., 46(5):462-9.
Stovroff, et al., (1989), Arch Surg., 124(1):94-9.

Affiliated with

Also associated with

Rating

Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potentiation of tumor necrosis factor (TNF) of interferon B1 (IF will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1846883